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Aims Human thoracic aortic aneurysms (TAAs) are characterized by extracellular matrix breakdown associated with pro-
gressive smooth muscle cell (SMC) rarefaction. These features are present in all types of TAA: monogenic forms
[mainly Marfan syndrome (MFS)], forms associated with bicuspid aortic valve (BAV), and degenerative forms. Initially
described in a mouse model of MFS, the transforming growth factor-b1 (TGF-b1)/Smad2 signalling pathway is now
assumed to play a role in TAA of various aetiologies. However, the relation between the aetiological diversity and the
common cell phenotype with respect to TGF-b signalling remains unexplained.
Methods
and results
This study was performed on human aortic samples, including TAA [MFS, n ¼ 14; BAV, n ¼ 15; and degenerative,
n ¼ 19] and normal aortas (n ¼ 10) from which tissue extracts and human SMCs and ﬁbroblasts were obtained.
We show that all types of TAA share a complex dysregulation of Smad2 signalling, independent of TGF-b1i n
TAA-derived SMCs (pharmacological study, qPCR). The Smad2 dysregulation is characterized by an SMC-speciﬁc,
heritable activation and overexpression of Smad2, compared with normal aortas. The cell speciﬁcity and heritability
of this overexpression strongly suggest the implication of epigenetic control of Smad2 expression. By chromatin
immunoprecipitation, we demonstrate that the increases in H3K9/14 acetylation and H3K4 methylation are involved
in Smad2 overexpression in TAA, in a cell-speciﬁc and transcription start site-speciﬁc manner.
Conclusion Our results demonstrate the heritability, the cell speciﬁcity, and the independence with regard to TGF-b1 and genetic
backgrounds of the Smad2 dysregulation in human thoracic aneurysms and the involvement of epigenetic mechanisms
regulating histone marks in this process.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
The transforming growth factor-b1 (TGF-b) signalling pathwayis a ubi-
quitous transduction system expressed in many cell types and involved
in numerous biological activities, including extracellular matrix syn-
thesis, cell survival, and differentiation.
1 TGF-b1 initiates several
intracellular pathways, including the Smad pathway.
2 Smads are tran-
scriptional factors critical for translating immediate signals from
TGF-b receptors to the nucleus. Combinatorial interactions of Smads
and variability of association with transcriptional factors induce a
context-dependenttranscriptionalregulationandasubstantialdiversity
in the Smad response.
3–5 Recent studies have demonstrated altered
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6 TGFBR2,
7
GLUT10
8) and non-syndromic [aneurysms associated with bicuspid
aortic valve (BAV) and degenerative
9] TAA, and have suggested that
the TGF-b pathway could play an important role in TAA pathology,
due to its involvement in the control of SMC survival and extracellular
matrix integrity
10,11 via a postulated increase in TGF-b1 bioavailabil-
ity.
12,13 TAA is characterized by an important aetiological diversity in
humans including (i) monogenic forms associated with mutations in
FBN1,
14 TGFBR1/2
7,15 [Marfan syndrome (MFS) and Loeys–Dietz syn-
drome (LDS)], MYH11,
16,17 ACTA2,
18 and GLUT10,
8 presenting a large
functionaldiversity,i.e. structureoftheextracellular matrix, contractile
and transporter functions,
19 (ii) aneurysms associated with BAV,
20 or
(iii) degenerative forms linked to ageing.
21,22 Increases in Smad2 acti-
vationanditsnucleartranslocationhavebeenobservedinTAA,regard-
less of aetiology.
6,7,9,23–25 However, several contradictory results
suggest a complex dysregulation of the TGF-b/Smad signalling
pathway.
26 Smad2 activation and the increase in stored TGF-b1 occur
concomittentlyintheaneurysmalmediabutthelocationofphosphory-
lated Smad2 and the sites of TGF-b1 storage and bioavailability do not
coincide.
9 Indeed, the activation of Smad2 is homogeneously observed
throughout the media, whereas the latent form of TGF-b1 is present
mainly in the outer media, near the adventitia. The increase in phos-
phorylated Smad2 is also present in patients bearing mutations in
TGFBR2,
9,24 despite the fact that these mutations induce a loss of func-
tion of the TGF-b receptors.
15
These preliminary observational data suggested an autonomization
of Smad expression as a speciﬁc arterial SMC phenotype associated
with TAA. The purpose of the present study was to elucidate the dys-
regulation of Smad2 signalling and to associate the modiﬁcations of
Smad2 expression with an epigenetic regulatory process in aortic
SMCs from syndromic and non-syndromic human TAAs.
2. Methods
2.1 Patients and aortic specimens
The clinical research protocol was approved by the local Ethics Commit-
tee (CPP 05 04 32, Ambroise Pare ´, Boulogne, France, April 2005; updated
in March 2008) and was in accordance with the principle of the Declara-
tion of Helsinki.
27 All patients gave informed consent.
Aneurysmal ascending aortic specimens were collected during aortic
surgery (Ho ˆpital Bichat). Forty-six specimens were divided into three
groups according to their clinical features and genetic background: MFS
related to mutations in FBN1 (n ¼ 12, mean age 39+15 years) or TGFBR2
(n ¼ 2, mean age 44+11 years), BAV (n ¼ 15, mean age 59+13 years),
and degenerative ascending aortic aneurysm (n ¼ 19, mean age 68+20
years). The clinical data associated with this series have been reported else-
where.
28 All specimens were from aneurysms of .5 cm in diameter.
Normal ascending aortas were obtained from organ transplant donors
(n ¼ 10) with the authorization of the French Biomedicine Agency
(PFS09-007) andinaccordancewiththe DeclarationofHelsinki.Aneurysmal
tissues were sampled in the outer curvature, the most dilated part of the
ascending aorta. Aortic tissue preparation consisted of an immediate dissec-
tion to separate medial and adventitial layers followed by either freezing or
enzymatic digestion to obtain SMC and ﬁbroblast cultures.
2.2 Primary cultures and in vitro stimulation
Medial andadventitial samples were incubated ineithercollagenaseand elas-
tase 0.1% or collagenase 0.3% solutions, respectively (3 h, 378C), to obtain
SMCs and ﬁbroblasts to be cultured.
29 All cells were routinely cultured in
smooth muscle cell (SMC) medium (Promocell) containing 5% foetal calf
serum (FCS), gentamicin-sulfate (50 mg/mL), amphotericin B (50 mg/mL),
insulin (5 mg/mL), and growth factors (human epidermal and ﬁbroblast
growth factors, respectively 0.5 and 2 mg/mL). Passages 3–6 were used for
experiments.Allstimulationswereperformedafter24 hincubationinserum-
freemedium.SMCsandﬁbroblastswerethenincubatedwithTGF-b1an d/or
anti-TGF-b1 (Sigma-Aldrich, St Louis, MO, USA) for 24 h.
2.3 siRNA transfection
To verify TGF-b1/Smad2 target gene speciﬁcity, we inhibited Smad2
expression by using an siRNA sequence targeting human Smad2.
Calcium phosphate-mediated transfection was performed. siRNA
duplexes were incubated with CaCl2 (2.5 M) and then added to HBSP sol-
ution (190 mM NaCl, 0.75 mM Na2HPO4, 6 mM glucose, 5 mM KCl,
25 mM HEPES). Human SMCs were transfected with a ﬁnal concentration
of 200 nM siRNA. TGF-b1 (5 ng/mL, 24 h) was added 48 h later. Finally,
Smad2 and target gene [connective tissue growth factor (CTGF) and
a-actin] expressions were quantiﬁed by qPCR 72 h after transfection.
2.4 Aortic tissue extraction
Extractions (protein, mRNA, and chromatin) were performed directly
from frozen aortic media and adventitia stored at 2808C. Aortic
samples were ﬁrst cryogenically pulverized in liquid nitrogen, using a
freezer mill (model 6750 SPEX SamplePrep). For protein, mRNA, and
chromatin isolation, homogenization of 100–300 mg of crushed aortic
powder was performed in the corresponding extraction buffer.
2.5 Reverse transcription-PCR
Total RNA was extracted from SMCs or ﬁbroblasts, using the EZNA kit
(Omega Biotek), according to the manufacturer’s directions. Reverse tran-
scription was performed using kits from Invitrogen (Carlsbad, CA, USA).
Real-time PCR was performed in the LightCycler system with SYBR
Green detection (Roche Applied Science) using speciﬁc primers (see Sup-
plementary material online, Table S1). The mRNA levels were normalized
to GAPDH mRNA.
2.6 Immunoblotting
Proteins were extracted from medial or adventitial tissues or SMCs.
Tissues or cells were homogenized in a lysis buffer [50 mM Tris (pH 8),
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 5 mM
EDTA], containing protease inhibitors and a serine/threonine and tyrosine
phosphatase inhibitors (Sigma-Aldrich). The protein concentration from
each sample was determined (Thermo Fisher Scientiﬁc, Rockford, IL,
USA). Extracts were separated by 10% sodium dodecyl sulfate–polyacri-
lamide gel electrophoresis (SDS–PAGE). Proteins were transferred to
polyvinylidene diﬂuoride membranes, blocked with 5% BSA-TBS-T [Tris-
buffered saline (pH 7.4)-0.1% Tween 20] for 1 h. Membranes were then
incubated overnight (48C) with primary antibodies: p-smad2/3 (0.5 mg/
mL), Smad2 (0.5 mg/mL), Smad7 (1 mg/mL; all from Santa Cruz Biotech-
nology), Smad4 (1 mg/mL, Cell Signaling Technology), a-actin (28 mg/
mL, Dako), SM-myosin (1 mg/mL, Abcam), or GAPDH (1.6 mg/mL, Bioval-
ley) and then washed with TBS-T and incubated with peroxidase-
conjugated anti-rabbit, anti-mouse, or anti-goat IgG (Jackson Laboratories)
for 1 h. The signal was detected using a chemiluminescence kit (ECL+ kit;
Amersham). Positive immunoreactive bands were quantiﬁed by densito-
metry. Protein levels were normalized to GAPDH protein levels. Immu-
noprecipitation (IP) of phosphorylated TGFbR1 (pTGFbR1) was
performed. An amount of 300 mg of total protein extracts were incubated
with TGFbR1 antibody (2 mg, Santa Cruz Biotechnology) for 2 h at room
temperature, and then incubated with Bio-Adembeads Protein G 0433
(30 mL/2 mg TGFbR1 antibody, Ademtech) overnight at 48C. Immunopre-
cipitates were washed ﬁve times in cold lysis buffer-TBS-T (1:1) and then
resuspended in sample buffer for analysis by SDS–PAGE. Phospho-serine
polyclonal antibody (2 mg/mL, Abcam) was used for immunoblotting.
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Chromatin immunoprecipitations (ChIPs) were performed on frozen
aneurysmal (Marfan: n ¼ 3; degenerative: n ¼ 3; BAV: n ¼ 3) and
control (n ¼ 5) media and adventitia. Tissue homogenates were cross-
linked with 1% formaldehyde for 15 min, and glycine (ﬁnal concentration
of 125 mM) was added. Chromatin shearing and IPs were performed using
histone ChIP kit (Diagenode), following the manufacturer’s instructions.
Chromatin shearing was veriﬁed by agarose gel migration, and chromatin
fragment lengths between 200 and 800 base pairs were obtained. IPs were
performed with H3K9/14ac, H3K4me, H3K9me2, H3K9me3, H4K5/8/12/
16ac, and H4K20me (1 mg/IP, Diagenode). After IP, DNA was isolated
from chromatin and puriﬁed. DNA from non-immunoprecipitated
sheared chromatin (INPUT) was also puriﬁed. PCR was then performed
using speciﬁc primers (see Supplementary material online, Table S1).
2.8 Statistical analysis
Values are expressed as means+SEM. For results expressed as box plots,
the median is shown. Upper and lower limits of boxes represent inter-
quartiles (25th and 75th), whereas upper and lower bars show percen-
tiles. The signiﬁcance of differences between groups was tested using
the Mann–Whitney non-parametric test. A value of P ≤ 0.05 was con-
sidered signiﬁcant.
See also Supplementary material online, Methods, for TGFbR2 trans-
fection and DNA methylation methods.
3. Results
3.1 Smad2 activation and overexpression in
TAA
Smad activation was measured in extracts of the medial layer from TAA
and ascending aorta. In agreement with previous studies,
6,7,9 pSmad2
levelswereincreasedintheTAAmediallayer(Figure1AandB)regardless
of aetiology: FBN1, TGFBR2, BAV, and degenerative, compared with
normal media (control) (P , 0.0001). Total Smad2 protein levels were
alsoincreasedinTAAmedialextracts(P , 0.001).Apositivecorrelation
was observed between pSmad2 and Smad2 protein expression (R
2 ¼
0.68; P , 0.0001) (Figure 1C). Smad2 activation and overexpression
were speciﬁc downstream to the TGF-b receptors since the activity
and expression levels of the other Smad-family proteins remained
unchanged (pSmad3, Smad4, and Smad7) (Figure 1A;S u p p l e m e n t a r y
material online, Figure S1A). Similarly, non-Smad pathways, RhoA and
MAPkinase pathways,
2 were not affected in TAA samples. RhoA target
expression (smooth muscle a-actin and smooth muscle-myosin) and
MAPkinase activation were similar in TAA and control medial extracts
(Figure 1A; Supplementary material online, Figure S1B). The response to
exogenous TGF-b1 and the constitutive nature of the Smad2 dysregula-
tion were next analysed in control and TAA-derived SMCs. In control
SMCs, basal levels of pSmad2 were low and treatment with TGF-b1
induced the phosphorylation and the nuclear translocation of Smad2. In
contrast,aconstitutivenuclearstainingofpSmad2wasobservedindepen-
dentlyoftheadditionofTGF-b1inTAA-derivedSMCs(Figure2A).Asfor
medial extracts, this constitutive activation wasspeciﬁc to Smad2since a
normal Smad3 phosphorylation induced by TGF-b1 was observed in
TAA-derived SMC cultures (Figure 2B).
3.2 Constitutive nature and speciﬁcity of
the Smad2 activation
To further explore the speciﬁcity of the Smad2 activation, Smad2
(CTGF) and non-Smad/RhoA (a-actin) targets were quantiﬁed.
2,30
Transfection of control SMCs with Smad2-siRNA speciﬁcally
decreases Smad2 expression (60%) (Figure 3A). Smad2 silencing
was associated with a signiﬁcant decrease in CTGF expression in
response to TGF-b1, whereas a-actin levels were not modiﬁed
(Figure 3A).
Increased basal levels of CTGF were observed in TAA-derived
SMCs compared with controls (P , 0.001) (Figure 3A; Supplementary
material online, Figure S2), regardless of aetiology. In contrast, no
differences in basal levels of a-actin were observed. CTGF expression
was not modulated by TGF-b1 in TAA-derived SMCs, contrasting
with the a-actin expression (Figure 3B). The effect of TGF-b1o n
a-actin expression was signiﬁcantly reduced in SMCs bearing
TGFBR2 mutations compared with controls (P , 0.01). Nevertheless,
the persistence of a high-basal CTGF expression was observed in
association with these genetic defects. Besides its constitutive
nature, Smad2 activation is characterized by its cell speciﬁcity and her-
itability. TGF-b1 treatment induced a similar increase in Smad2 acti-
vation in control and aneurysmal ﬁbroblasts, except for samples
belonging to the TGFBR2 subgroup. In this case, the regulation of
ﬁbroblast CTGF expression by TGF-b1 was signiﬁcantly decreased
( 50%) compared with ﬁbroblasts from controls and from the
other types of TAA (Figure 3C).
3.3 Autonomization of the Smad2
activation
To understand the relationship between the constitutive activation of
Smad2 and the activity of TGFbR2, we performed transient transfec-
tions with wild-type or mutated [Q508Q (stop codon) and R537C
(missense)] TGFbR2 in 293 cells (see Supplementary material
online, Methods; Figure S3). A lack of phosphorylation and nuclear
translocation of Smad2/3 was observed in Q508Q-TGFbR2- and
R537C-TGFbR2-transfected 293 cells, incubated with TGF-b1, indi-
cating a loss of function, further supporting the functional dissociation
of Smad2 activation from TGF-b receptors.
15 Quantiﬁcation of
TGFbR2 and TGFbR1 mRNA levels revealed no signiﬁcant differ-
ences in TAA-derived SMCs compared with controls. Next, we esti-
mated WT and mutated TGFbR2 mRNA expression in SMCs bearing
Q508Q and R537C mutations. In these cases, expression of WT and
mutated TGFbR2 mRNA was equivalent (see Supplementary material
online, Figure S3).
TGF-b receptor complex functionality was estimated by measur-
ing pTGFbR1 protein levels in medial extracts. pTGFbR1 levels
were similar in control and TAA medial extracts, except for
those carrying TGFBR2 mutations (Q508Q and R537C) in which
the pTGFbR1 level was signiﬁcantly lower compared with both con-
trols and other forms of TAA (P , 0.05) (Figure 4A). In control SMC
cultures, incubation with TGF-b1 induced a signiﬁcant increase in
pTGFbR1, CTGF, and a-actin levels (P , 0.01), an effect abrogated
by the anti-TGF-b1 antibody (Figure 4B). In TAA-derived SMCs
(except TGFBR2 subgroup), incubation with TGF-b1 induced a
similar increase in pTGFbR1 and a-actin levels (but not in CTGF
mRNA) compared with controls. In the case of TGFBR2 mutations,
a defect in TGFbRI phosphorylation and a-actin expression induced
by TGF-b1 was observed. Nevertheless, a constitutive increase in
CTGF levels was detected. These results provide evidence of the
autonomy of Smad2 activation with respect to TGFbR1/2 activity
in human TAA-derived SMCs.
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Smad2 perturbation
Basal Smad2 mRNA expression was constitutively increased in TAA-
derived SMCs compared with control SMCs (P , 0.0001) (Figure 5A),
regardless of aetiology. In TAA-derived SMCs, mRNA quantiﬁcation
performed over three passages (passages 3–5) showed an increase
in both Smad2 and CTGF expression which was maintained over
several cycles of cell division. Next, control SMCs were incubated
with conditioned medium from TAA-derived SMCs. The incubation
did not induce increases in either activation (CTGF mRNA level) or
expression of Smad2 (Figure 5B). Similar results were obtained with
TAA-derived ﬁbroblasts incubated with conditioned medium from
TAA-derived SMCs (see Supplementary material online,Figure S4A).
These results eliminate any autocrine TGF-b1 signalling as the cause
of the constitutive Smad2 activation and demonstrate that the
Smad2 perturbation, observed in all types of TAA, consists of a con-
stitutive activation and overexpression of Smad2 that are independent
of extracellular TGF-b1 and of TGF-b receptor activity.
In contrast with SMCs, no difference in basal CTGF mRNA
expression was found between aneurysmal and control ﬁbroblasts
(Figure 5C).
Figure 1 Smad2 activation and overexpression in aortic extracts and SMC cultures. (A) Immunoblots performed with aortic medial extracts
showing increased phosphorylated Smad2 and total Smad2 levels in TAA extracts compared with controls. No differences in pSmad3, a-actin,
and SM-myosin protein levels are observed. (B) Quantiﬁcation of pSmad2 (relative pSmad2 protein level: TGFBR2: 2.14+0.94; FBN1: 3.03+1.47;
degenerative: 2.92+1.64; BAV: 2.35+1.38 vs. control: 0.64+0.26; *P , 0.0001) and Smad2 (TGFBR2: 1.60+0.19; FBN1: 1.92+1.4; degenerative:
1.86+1.36; BAV: 1.85+1.28 vs. control: 0.44+0.15; *P , 0.001). Results are expressed as relative protein levels: pSmad2/GAPDH or Smad2/
GAPDH. (C) Positive correlation between pSmad2 and Smad2 protein levels in TAA (all aetiologies included). R
2 ¼ 0.68. No positive correlation
was observed in control extracts (R
2 ¼ 0.003).
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in TAA
The transmission to daughter cells
31 and the cell-speciﬁcity of the dys-
regulation of Smad2 expression in TAA strongly suggest the impli-
cation of epigenetic mechanisms. Two putative transcription start
sites (TSSs) have been identiﬁed in the Smad2 promoter: 1a TSS
and 1b TSS.
32 Depending on the TSS implicated and possible alterna-
tive splicing, three transcriptional variants containing the same coding
region but different 5′ untranslated regions were generated: 1a, 1b,
and 1a + 1b (Figure 5D). The expression of each updated transcrip-
tional variant was estimated by PCR. Transcriptional variants 1a and
1a + 1b were overexpressed in TAA-derived SMCs compared with
controls. In contrast, no difference in 1b variant expression was
found in TAA-derived SMCs vs. control. These data indicate that
the constitutive Smad2 overexpression was associated with an
increase in the expression of Smad2 variants, depending only on 1a
TSS. This increase was not dependent on variations in Smad2
mRNA stability (see Supplementary material online, Figure S4B),
suggesting an activation of the Smad2 promoter.
Figure 2 Constitutive activation and phosphorylation of Smad2 in TAA. (A) Constitutive activation of Smad2 in cultured aneurysmal SMCs. Immu-
nostaining of pSmad2/3, performed after stimulation by TGF-b1 (5 ng/mL; 24 h), shows a nuclear accumulation of pSmad2/3 induced by TGF-b1i n
control SMCs. Increased nuclear accumulation of pSmad2/3 is observed in aneurysmal SMCs (magniﬁed in inset) independently of the addition of
exogenous TGF-b1. Nuclear counterstaining: DAPI. Scale bar: 50 mm. (B) pSmad2/3 immunoblotting performed with protein extracts from
control and aneurysmal SMCs. Results are expressed as means+SEM. TGF-b1 induces a signiﬁcant increase in pSmad2 levels in control SMCs
(*P , 0.01) and in pSmad3 levels in both control and aneurysmal SMCs (*P , 0.01). A constitutive increase in pSmad2 is observed in aneurysmal
SMCs (#P , 0.001) compared with non-treated SMCs. Results expressed as pSmad2/GAPDH or pSmad3/GAPDH.
D. Gomez et al. 450Figure 3 Speciﬁcity of Smad2 activation. (A) Smad2 silencing by siRNA targeting Smad2 in control SMCs. Smad2 siRNA transfection decreases
Smad2 expression (P , 0.0001). Smad2 mRNA relative level was quantiﬁed by qPCR (Smad2 siRNA: 0.0217+0.05; cont siRNA 0.5+0.133; non-
transfected SMCs: 0.5+0.06). Transfected SMCs were treated with TGF-b1 (5 ng/24 h). Smad2 silencing induces a signiﬁcant lack of CTGF
expression in response to TGF-b1, whereas it has no effect on a-actin expression (normalization by GAPDH mRNA expression). (B) Effect of
TGF-b1 treatment on CTGF (Smad2 target) and a-actin (non-Smad2 target) expression. All data are means+SEM. CTGF mRNA levels are signiﬁ-
cantly increased with TGF-b1 treatment of control SMCs (#P , 0.001). Basal CTGF levels are signiﬁcantly increased in aneurysmal SMCs compared
with controls (*P , 0.0001). No difference is observed between aetiologies. Increased a-actin levels are induced by TGF-b1 treatment in both control
and aneurysmal SMCs (*P , 0.001) (left panel). Results are represented as the ratio between treated and non-treated levels and expressed as a
fold-increase compared with the non-treated condition (right panel). *Signiﬁcant increase in CTGF and a-actin ratio compared with non-treated
level (P , 0.0001), #signiﬁcant decrease in a-actin ratio in TGFBR2 compared with control and aneurysmal SMCs (P , 0.05). (C) Quantiﬁcation of
CTGF mRNA levels in control and aneurysmal ﬁbroblasts (control: n ¼ 5; TGFBR2: n ¼ 2; FBN1: n ¼ 4; degenerative: n ¼ 4; BAV: n ¼ 3). *Signiﬁcant
increase in CTGF ratio compared with non-treated level (P , 0.01), #signiﬁcant decrease in CTGF ratio in TGFBR2 compared with control and
aneurysmal ﬁbroblasts (P , 0.05).
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tails control Smad2 overexpression in TAA
Modiﬁcations of epigenetic markers carried by DNA or histones have
already been reported to be associated with an increase in promoter
activity.
33,34 Consequently, we investigated epigenetic markers on the
Smad2 promoter in TAA and control aortic media and adventitia. We
ﬁrst hypothesized that the CpG-rich regions of the Smad2 promoter
could be hypomethylated. However, for both TAA and control DNA,
the Smad2 promoter appeared unmethylated by bisulﬁte sequencing
(see Supplementary material online, Methods; Figure S5), suggesting
that differential DNA methylation is not implicated in Smad2
promoter activation in TAA. In contrast, increased acetylated and
methylated lysine staining was observed in TAA-derived SMC cul-
tures, and colocalized with histone H1 staining in the nucleus
(Figure 6A). These results suggest the involvement of covalent modiﬁ-
cations of histone tails, triggering chromatin remodelling in TAA. Our
next step was to determine whether epigenetic markers were differ-
entially present on the alternate Smad2 promoters. Precipitation of
H3K9/14ac (ChIP) revealed an increase in H3 acetylation on the
Smad2 promoter, in the vicinity of the 1a TSS in TAA extracts com-
pared with controls (P , 0.01) (Figure 6B). Similar results were
obtained performing ChIP assays with an H3K4me-speciﬁc antibody
(P , 0.05). No changes in H3K9/14 acetylation and H3K4 methylation
levels have been observed associated with the 1b TSS Smad2 promo-
ter (Figure 6C). H3 acetylation and methylation were speciﬁcally
Figure 4 TGF-b receptor activity. (A) Estimation of TGFbR1/2 activity by measurement of TGFbR1 phosphorylation. Results are expressed as the
ratio of pTGFbR1/TGFbR1. *Signiﬁcant decrease in TGFbR1 phosphorylation in aneurysmal media from patients with TGFBR2 mutations (Q508Q and
R357C) compared with controls and other types of TAA (P , 0.05). (B) Dissociation between Smad2 activation and TGF-b receptor activity in aneur-
ysmal SMCs. *P , 0.01, treated vs. non-treated conditions.
#P , 0.05 vs. control.
D. Gomez et al. 452associated with the 1a TSS Smad2 promoter, corresponding to the
speciﬁc increase in 1a and 1a + ab transcriptional variants. Moreover,
these epigenetic markers on histone H3 were speciﬁc of the TAA
media and were not observed in TAA adventitial extracts
(Figure 6D). These observations correlated with the cell speciﬁcity
of Smad2 expression. Contrasting with H3 histone, H4 acetylation
and methylation (H4K5/8/12/16ac and H4K20me) levels were
similar in TAA extracts and controls. Furthermore, no differences in
repressive epigenetic histone H3 modiﬁcations (H3K9me2,
H3K9me3) were found between TAA medial extracts and controls
(see Supplementary material online, Figure S6). Thus, we have
observed a speciﬁc increase in histone H3 acetylation (H3K9/14ac)
and methylation (H3K4me) in the medial layer of TAAs of all
aetiologies.
4. Discussion
Our results demonstrate, for the ﬁrst time, the heritability, the cell
speciﬁcity, and the independence with regard to extracellular
ligands (TGF-b1) and genetic background of the Smad2 dysregulation
Figure 5 Heritability and cell speciﬁcity of the Smad2 overexpression and activation. (A) Smad2 and CTGF mRNA levels are quantiﬁed over three
successive passages between passages 3 and 5. SMCs were cultured in free-serum SMC medium 24 h before RNA extraction. Increased Smad2 and
CTGF expression is observed in aneurysmal SMCs compared with controls, whatever the passage (*P , 0.001). (B) Incubation of control SMCs with
conditioned medium from aneurysmal SMCs (24 h), followed by the quantiﬁcation of CTGF and Smad2 mRNA expression. No effect of the incubation
is visualized on Smad2 activation (CTGF mRNA level) and Smad2 expression. (C) Quantiﬁcation of Smad2 mRNA levels in aneurysmal and control
ﬁbroblasts shows no difference in Smad2 expression. (D) Representation of SMAD2. SMAD2 has two TSSs. Three mRNA variants are synthesized: 1a,
1b, and 1a + 1b*. Quantiﬁcation of each variant is performed using speciﬁc primers (arrows). Representative migration showing a speciﬁc overexpres-
sion of Smad2 mRNA variants 1a and 1a + 1b in aneurysmal SMCs compared with controls, whatever the aetiology.
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results in its activation and its overexpression in human TAAs, regard-
less of aetiology. The speciﬁc Smad2 overexpression is associated
with modiﬁcations of the histone H3 marker pattern in the vicinity
of 1a TSS on the Smad2 promoter, in pathological SMCs. The invol-
vement of such an epigenetic mechanism provides evidence of the
possible establishment of a sustained modiﬁed phenotype of SMCs
in chronic cardiovascular diseases.
The perturbations of Smad2 signalling and expression are present in
the media of patients with MFS or LDS, regardless of the mutations
involved (FBN1 and TGFBR2), as described previously.
7 Our article
demonstrates clearly a functional dissociation between the Smad2
activation and the activity of the TGF-b1 receptors in the human
aneurysmal media. The loss of function induced by the TGFBR2
mutation is effective in adventitial ﬁbroblasts or in vascular SMCs
for the non-Smad2/TGF-b1 pathway, but is overwhelmed in TAA-
derived SMCs. SMCs from all types of TAA acquire autonomy in
Smad2 activation with regard to the canonical TGF-b1 pathway invol-
ving the interaction of TGF-b1/TGF-b receptors. These ﬁndings also
explain the lack of colocalization within the aneurysmal tissue
Figure 6 Increase in histone acetylation (H3K9/14) and methylation (H3K4) on Smad2 promoter. (A) Increased acetylated and methylated lysine
staining (red) is observed in aneurysmal SMCs and colocalizes with H1 histone staining (green) in the nucleus. Scale bar: 50 mm. (B–D) ChIP per-
formed with aneurysmal and control media (B and C) or adventitia (D). After ChIP, PCR is performed with primers annealing speciﬁc sequences
upstream to 1a TSS (B and D) or 1b TSS (C). Representative migrations of immunoprecipitated (IP) and non-immunoprecipitated (INPUT)
samples are shown for each precipitation. An increase in H3K9/14ac and H3K4me is observed upstream to the 1a TSS, only in aneurysmal SMCs
(all aetiologies included, no difference between aetiologies). Results are expressed as%IP/INPUT. *Signiﬁcant increase in H3K9/14ac (TAA:
36.4+13.3 vs. control: 13.6+1.9; P , 0.01) and H3K4me (TAA: 14.7+10.5 vs. control: 1.8+1.6; P , 0.05) is observed in TAA (all aetiologies
included) compared with control.
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9 An
important observation of this study is the signalling speciﬁcity of the
dysregulation exclusively relating to Smad2 and its downstream
pathway. Our results, associating Smad2 and CTGF perturbations,
are in accordance with previous studies.
30 Moreover, Smad2 silencing
proves clearly the independence of a-actin expression with respect to
Smad2. Smooth muscle a-actin (ACTA2) is known to be dependent on
TGF-b1 via the RhoA signalling pathway.
2 The fact that a-actin
expression increases in human TAA SMCs proves that these cells
can ‘respond’ to TGF-b1 and that the dysregulation is limited to the
Smad2 pathway. CTGF, known to be a TGF-b1/Smad target gene,
can itself activate the TGF-b1 signalling pathway by its direct
binding to TGF-b1. This interaction is associated with an activation
of TGF-b1 signalling.
35 Thus, although CTGF overexpression can
lead to TGF-b1 signalling activation, the present data do not
support the idea of an autocrine loop (Figure 5). In contrast, they
strengthen the concept of autonomous intracellular Smad2 activation.
The autonomous and constitutive overexpression of Smad2 is
associated with basal hyperacetylation and hypermethylation of
lysine residues. More precisely, this modulation of histone markers
concerns speciﬁcally H3K9/14ac and H3K4me on the Smad2 promo-
ter. These epigenetic markers are associated with an increase in tran-
scription activation,
36,37 strongly suggesting a direct association
between histone H3 acetylation and methylation and Smad2 overex-
pression. Moreover, a spatial speciﬁcity is observed on the Smad2
promoter since H3K9/14ac and H3K4me are only increased in the
vicinity of the 1a TSS on which the transcription variants overex-
pressed in TAA depend (1a and 1a + 1b). The present study
focuses on the transcriptional regulation inducing Smad2 overexpres-
sion. However, this process can be associated with modiﬁcations in
Smad2 protein stability. Indeed, modulation of Smad stability (degra-
dation via the ubiquitin–proteasome pathway) plays a major role in
the negative feedback. Smad ubiquitination is catalysed by enzymatic
systems, including the ubiquitin ligase E3 and associated proteins,
and Smurf (Smad ubiquitin regulatory factor) 1 and 2.
38,39 Smurf
targets C-terminally phosphorylated Smad2 which involves ubiquitina-
tion and degradation by proteasomes. A deﬁcit in this process appears
not to be the main mechanisms responsible for the global increase in
Smad2 and pSmad2. Nevertheless, the investigation of protein stability
could permit the evaluation of the potential cooperation between
these two mechanisms.
The activation and the overexpression of Smad2 are speciﬁc of
TAA-derived SMCs from the media. Such dysregulation was not
observed in the adjacent adventitial ﬁbroblasts. Furthermore, the
increase in H3 acetylation and methylation is speciﬁcally observed
in the media but not in the adventitia. This cell speciﬁcity raises the
question of the trigger of the epigenetic activation of Smad2, which
is a crucial point in the understanding of the global process of aneur-
ysm progression, suggesting that the genetic background, i.e. the FBN1
and TGFBR2 mutations, is not the direct cause of the Smad2 pertur-
bation but could initiate long-term environmental modiﬁcations
leading to epigenetic reprogramming. Vascular SMCs possess plasticity
which allows them to modulate their phenotype in response to
changes in environmental cues, such as mechanical stress, matrix
integrity, and cell–matrix interaction.
40,41 In TAA, the aetiological
diversity suggests several potential triggers: haemodynamic/rheologi-
cal modiﬁcations, protease activation, extracellular matrix degra-
dation, mutations, or any combination of these events. Phenotypic
modulation is associated with speciﬁc gene expression which could
be regulated by epigenetic marks, chromatin remodelling, and speciﬁc
SMC transcription factor binding.
42
We clearly observed an increase in basal Smad2 levels in both
medial extracts and cultured SMCs. This overexpression presents a
strong heritable character since it is sustained over several passages
without the addition of any cytokines or growth factors. The mainten-
ance of this Smad2 overexpression over several cycles of cell division
and the participation of epigenetic regulation on the Smad2 promoter
are consistent with the notion of epigenetic memory.
31,43 Our study
demonstrates the implication of epigenetic mechanisms (sustained
modulation of histone marks) in the development of a pathological
phenotype of the vascular SMCs in human TAA. Such phenotypic
modulation can be associated with the overexpression of the embryo-
nic form of the smooth muscle myosin which was previously observed
in the media of TAA, regardless of aetiology.
9 These observations
indicate the possible involvement of a de-differentiation process in
TAA-derived SMCs, induced by environmental or genetic pertur-
bations. De-differentiation and phenotypic modulation are processes
that are consistent with the notions of autonomy, heritability, cell
speciﬁcity, and epigenetic regulation
44 observed in chronic pathol-
ogies such as TAA.
31
Together, these results demonstrate that all types of TAA present
the same modes of dysregulation of Smad2 expression and activation,
which are constitutive, heritable, and cell speciﬁc. This constitutive
overexpression is associated with modiﬁcations of the histone H3
marker patterns in the vicinity of 1a TSS on the Smad2 promoter.
The importance of epigenetic reprogramming and how chromatin
modulation regulates SMC reprogramming might provide new insights
into the onset and progression of TAA and other chronic vascular
diseases.
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